Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURA-1 depemokimab in adults with COPD and type 2 inflammation
NL-OMON58895Phase 3Recruiting
- Sponsor
- GSK
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of depemokimab, sponsored by GSK. Started Apr 2026; status: recruiting.
02
Drugs
depemokimab
Beyond the preview
Go deeper on NL-OMON58895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58895.